SC-VC-PAB-DM1

• CAT Number: I017834
• CAS Number: 2259318-47-1
• Molecular Formula: C61H82ClN9O19
• Molecular Weight: 1280.81
• Purity: ≥95%
• Synonyms: (2,5-dioxopyrrolidin-1-yl) 6-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexanoate
• InChI: InChI=1S/C61H82ClN9O19/c1-33(2)52(67-46(72)18-11-12-19-50(76)90-71-47(73)24-25-48(71)74)55(78)66-40(16-14-26-64-57(63)80)54(77)65-39-22-20-37(21-23-39)32-86-59(82)69(7)36(5)56(79)88-45-30-49(75)70(8)41-28-38(29-42(84-9)51(41)62)27-34(3)15-13-17-44(85-10)61(83)31-43(87-58(81)68-61)35(4)53-60(45,6)89-53/h13,15,17,20-23,28-29,33,35-36,40,43-45,52-53,83H,11-12,14,16,18-19,24-27,30-32H2,1-10H3,(H,65,77)(H,66,78)(H,67,72)(H,68,81)(H3,63,64,80)/b17-13+,34-15+/t35-,36+,40+,43+,44-,45+,52+,53+,60+,61+/m1/s1
• InChIKey: LXJMPVKQZDSAAC-OGMVYAKQSA-N
• SMILES: C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCC(=O)ON6C(=O)CCC6=O)C)\C)OC)(NC(=O)O2)O

SC-VC-PAB-DM1（Cat No.:I017834）is an antibody–drug conjugate (ADC) linker–payload system combining a cleavable valine-citrulline (VC) dipeptide linker with para-aminobenzyloxycarbonyl (PAB) self-immolative spacer and DM1, a potent maytansinoid tubulin inhibitor. The VC-PAB linker ensures stability in circulation but undergoes enzymatic cleavage inside target cells, releasing DM1 to disrupt microtubule dynamics and induce apoptosis. This design enhances selective cytotoxicity while minimizing systemic toxicity. SC-VC-PAB-DM1 is widely studied in oncology research for evaluating targeted therapies, ADC pharmacokinetics, and strategies to improve cancer drug delivery and therapeutic outcomes.